Overview
Drug-induced erythema multiforme is a hypersensitivity reaction characterized by the development of target lesions and other skin manifestations triggered by certain medications, including vinorelbine. 1Diagnosis
Clinical presentation includes typical target lesions, mucosal involvement, and sometimes systemic symptoms.
No specific diagnostic tests; diagnosis is primarily clinical.
Grading systems like the Modified Severity Score for Erythema Multiforme (MSE-EM) can assess severity 1.Management
First-line treatment: Discontinue the offending drug.
Adjunctive treatments:
- Corticosteroids (e.g., prednisone) for moderate to severe cases 1.
- Antibiotics if secondary infection occurs.
- Supportive care including wound management and hydration.Special Populations
Dose adjustment: Higher doses of vinorelbine (≥40 mg) significantly increase the risk of venous irritation, suggesting dose reduction may mitigate adverse effects in vulnerable populations 1.Key Recommendations
Reduce vinorelbine dose to <40 mg to decrease the incidence of venous irritation and potential erythema multiforme-like reactions (Evidence: Moderate) 1
Increase the volume of normal saline for drug dissolution (e.g., from 50 mL to 100 mL) to mitigate irritation symptoms (Evidence: Moderate) 1
Discontinue the causative medication promptly upon diagnosis of drug-induced erythema multiforme (Evidence: Expert opinion) 1References
1 Yamada T, Egashira N, Watanabe H, Nagata K, Yano T, Nonaka T et al.. Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2012. link